| Jila Noorikolouri, MD | |
|
608 Stanton L Young Blvd, Oklahoma City, OK 73104-5065 | |
| (405) 271-6060 | |
| (405) 271-3013 |
| Full Name | Jila Noorikolouri |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 25 Years |
| Location | 608 Stanton L Young Blvd, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023548328 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | HSE24695 (Florida) | Secondary |
| 207WX0108X | Ophthalmology - Uveitis And Ocular Inflammatory Disease | 35869 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dean Mcgee Eye Institute | 3779495353 | 40 |
News Archive
Limited, low-dose infusions of a widely used anesthetic drug may relieve the often intolerable and debilitating pain of Complex Regional Pain Syndrome (CRPS), a Penn State Milton S. Hershey Medical Center researcher found.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) announces an increase to the size of its non-brokered private placement to a total of approximately 2.27 million units (the "Units") at a price of $0.55 per Unit, from the previously announced total of approximately 1.8 million Units, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant") with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share") at a price of $0.80 per Warrant Share for a term of thirty-six (36) months following the date of issuance, for gross proceeds of up to $1.25 million (the "Offering").
A revolutionary discovery regarding motile cancer cells made by research scientists at VTT Technical Research Centre of Finland and the University of Turku is challenging previous conceptions.
Hemosphere, Inc., a private medical device company, has completed a late round of venture capital financing totaling $9.3 million. The company has developed the HeRO® Vascular Access Device, which provides access for hemodialysis - the process of filtering waste products from blood when kidneys are in renal failure - similar to a conventional graft.
Study led by St. Jude Children's Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.
› Verified 2 days ago
| Entity Name | Dean Mcgee Eye Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245209675 PECOS PAC ID: 3779495353 Enrollment ID: O20031103000297 |
News Archive
Limited, low-dose infusions of a widely used anesthetic drug may relieve the often intolerable and debilitating pain of Complex Regional Pain Syndrome (CRPS), a Penn State Milton S. Hershey Medical Center researcher found.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) announces an increase to the size of its non-brokered private placement to a total of approximately 2.27 million units (the "Units") at a price of $0.55 per Unit, from the previously announced total of approximately 1.8 million Units, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant") with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share") at a price of $0.80 per Warrant Share for a term of thirty-six (36) months following the date of issuance, for gross proceeds of up to $1.25 million (the "Offering").
A revolutionary discovery regarding motile cancer cells made by research scientists at VTT Technical Research Centre of Finland and the University of Turku is challenging previous conceptions.
Hemosphere, Inc., a private medical device company, has completed a late round of venture capital financing totaling $9.3 million. The company has developed the HeRO® Vascular Access Device, which provides access for hemodialysis - the process of filtering waste products from blood when kidneys are in renal failure - similar to a conventional graft.
Study led by St. Jude Children's Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jila Noorikolouri, MD 608 Stanton L Young Blvd, Oklahoma City, OK 73104-5065 Ph: (405) 271-6060 | Jila Noorikolouri, MD 608 Stanton L Young Blvd, Oklahoma City, OK 73104-5065 Ph: (405) 271-6060 |
News Archive
Limited, low-dose infusions of a widely used anesthetic drug may relieve the often intolerable and debilitating pain of Complex Regional Pain Syndrome (CRPS), a Penn State Milton S. Hershey Medical Center researcher found.
Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) announces an increase to the size of its non-brokered private placement to a total of approximately 2.27 million units (the "Units") at a price of $0.55 per Unit, from the previously announced total of approximately 1.8 million Units, each Unit comprised of one Common Share of the Corporation and one-half of one Common Share purchase warrant ("Warrant") with each whole Warrant entitling the holder to purchase an additional Common Share ("Warrant Share") at a price of $0.80 per Warrant Share for a term of thirty-six (36) months following the date of issuance, for gross proceeds of up to $1.25 million (the "Offering").
A revolutionary discovery regarding motile cancer cells made by research scientists at VTT Technical Research Centre of Finland and the University of Turku is challenging previous conceptions.
Hemosphere, Inc., a private medical device company, has completed a late round of venture capital financing totaling $9.3 million. The company has developed the HeRO® Vascular Access Device, which provides access for hemodialysis - the process of filtering waste products from blood when kidneys are in renal failure - similar to a conventional graft.
Study led by St. Jude Children's Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.
› Verified 2 days ago
Vinay Ashok Shah, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9821 S May Ave Ste C, Oklahoma City, OK 73159 Phone: 405-691-0505 Fax: 405-691-0507 | |
Cynthia A Bradford, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-7873 | |
Dr. Brian Keith Firestone, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-6060 Fax: 405-271-7873 | |
David W Parke Ii, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-1092 | |
Gary Waine Wilson, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 7101 Nw Expressway, Suite 335, Oklahoma City, OK 73132 Phone: 405-722-2020 Fax: 405-516-6126 | |
David W. Jackson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 608 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-1095 |